Caribou Biosciences Stock

cariboubio.comBioTechFounded: 2011Funding to Date: $41.55MM

Caribou Biosciences is a leading clinical-stage CRISPR genome editing biotechnology company developing an internal pipeline of off-the-shelf, genome-edited CAR-T and natural killer (NK) cell therapies.

Register for Details

For more details on financing and valuation for Caribou Biosciences, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Rachel Haurwitz Ph.D
Co-Founder, Board Member, President and Chief Executive Officer
Barbara McClung
Chief Legal Officer and Corporate Secretary
Steven Kanner Ph.D
Chief Scientific Officer
Edny Inui
Director, Business Development
Timothy Herpin Ph.D
Chief Business Officer
Martin Jinek Ph.D
Co-Founder & Scientific Advisor
James Berger
Co-Founder
Chris Fuller
Vice President, Informatics
Scott Gradia Ph.D
Vice President of Platform Research
Jennifer Doudna Ph.D
Co-Founder & Scientific Advisor

Board Members

Natalie Sacks MD
Philip Austin
Anterra Capital
Rachel Haurwitz Ph.D
Robert Weisskoff Ph.D

Other companies like Caribou Biosciences in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced the publication of a new study demonstrating human genome engineering wi